Biological variation of free β chorionic gonadotropin and pregnancy-associated plasma protein A in first trimester pregnancies

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 2, 2011, Pages 291-295

  Sennels, Henriette P ^a   Jørgensen, Finn Stener ^a   Sørensen, Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Down syndrome; free b human chorionic gonadotropin; pregnancy associated plasma protein A; risk; variability

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FIRST TRIMESTER PREGNANCY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REPRODUCIBILITY OF RESULTS; TIME FACTORS; YOUNG ADULT;

EID: 79952099355     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.054     Document Type: Article

References (20)

1. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246. (Pubitemid 28270247)
2. Christiansen M, Larsen SO. Precision of risk in multidimensional likelihood ratio based screening with first trimester screening for Down's syndrome as a special case. J Med Screen 2001;8:61-4. (Pubitemid 32664884)
3. Christiansen M, Hogdall EV, Larsen SO, Hogdall C. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. Prenat Diagn 2002;22:385-7. (Pubitemid 34538566)
4. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567-76. (Pubitemid 35316289)
5. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003;40:219-31. (Pubitemid 36560992)
6. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
7. Fraser CG. Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta 2004;346:19-24. (Pubitemid 38952686)
8. Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? Prenat Diagn 2002;22:903-6.
9. Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed. Philadelphia, PA: Elsevier Saunders, 2006:2412pp.
10. Pekonen F, Alfthan H, Stenman UH, Ylikorkala O. Human chorionic gonadotropin (hCG) and thyroid function in early human pregnancy: circadian variation and evidence for intrinsic thyrotropic activity of hCG. J Clin Endocrinol Metab 1988;66:853-6.
11. Rotmensch S, Celentano C, Elliger N, Sadan O, Lehman D, Golan A, et al. Diurnal variation of human chorionic gonadotropin beta-core fragment concentrations in urine during second trimester of pregnancy. Clin Chem 2001;47:1715-7. (Pubitemid 32781593)
12. Nakajima ST, McAuliffe T, Gibson M. The 24-hour pattern of the levels of serum progesterone and immunoreactive human chorionic gonadotropin in normal early pregnancy. J Clin Endocrinol Metab 1990;71:345-53.
13. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493-502.
14. Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women. Prenat Diagn 2007;27:303-11.
15. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;i:1287-93.
16. Gaudry P, Grange G, Lebbar A, Choiset A, Girard S, Goffinet F, et al. Fetal loss after amniocentesis in a series of 5780 procedures. Fetal Diagn Ther 2008;23:217-21. (Pubitemid 351555844)
17. Palomaki GE, Wright DE, Summers AM, Neveux LM, Meier C, O'Donnell A, et al. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. Prenat Diagn 2006;26:730-9. (Pubitemid 44252252)
18. Spencer K. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays. Ann Clin Biochem 2005;42:30-40.
19. Kirkegaard I, Petersen OB, Uldbjerg N, Torring N. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat Diagn 2008;28:839-44.
20. Spencer K. Aneuploidy screening in the first trimester. Am J Med Genet C Semin Med Genet 2007;145C:18-32. (Pubitemid 46427651)